Secondary Prevention of Stroke Through Non-drug Therapeutic Weight Reduction

NCT ID: NCT01721538

Last Updated: 2012-11-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SCENARIO is a trial to investigate the role of non-drug weight reduction in secondary prevention of stroke. It is a single-blinded, randomized, controlled multicentre trial with two arms. The therapy arm is participating in a comprehensive weight reducing program, whereas the control group takes part in a lecture on healthy nutrition. The primary study objective is to assess the efficacy of non-drug therapeutic weight reduction in the secondary prevention of stroke. Secondary objectives are functional outcome, cognitive status, post stroke depression, and health-related quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke Obesity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

stroke prevention obesity weight reduction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Therapy arm

Non-drug therapeutic weight reduction program (15 weeks)

Group Type EXPERIMENTAL

Weight reduction program

Intervention Type OTHER

Control arm

Lecture on healthy nutrition (1 hour)

Group Type PLACEBO_COMPARATOR

Lecture on healthy nutrition

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Weight reduction program

Intervention Type OTHER

Lecture on healthy nutrition

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of ischemic stroke
* Age: 20 - 85 years
* BMI ≥ 25.0 kg/m² or waist circumference in men ≥ 94cm and in women ≥ 80cm
* Functional impairment, which would allow to participate in weight reduction program (mRS 0-4, NIHSS 0-12)
* Patient must be capable of understanding informed consent
* Written informed consent for participation in the study

Exclusion Criteria

* Intracerebral hemorrhage as primary cause of stroke (secondary hemorrhage is not an exclusion criterion)
* Speech disturbance (aphasia or sever dysarthria)
* Dimming of consciousness
* Stroke due to arterial dissection or coagulation disorder
* Drug-related weight changes during previous 3 months
* Changes in appetite influencing medication listed in appendix during previous 3 months
* Bariatric surgery in the past
* Diabetes mellitus with a history of severe ketoacidosis
* Pregnancy or nursing
* Severe co-morbid disorders, e.g.:

* AV-Block ≥ 2nd degree
* Heart insufficiency (NYHA \> 2)
* Pericarditis, pericardial effusion
* Severe kidney insufficiency (Creatinine \> 3 mg/dl; Urea \> 150 mg/dl)
* Hepatic insufficiency (GOT \> 3 x ULN; GPT \> 3 x ULN)
* Severe psychiatric disease within the last six months (psychosis, suicide attempts)
* Chronic alcohol addiction or drug addiction
* HIV- or hepatitis infection
* Bleeding peptic ulcer (unless there is radiological evidence of healing 6 months prior to start of obesity program)
* Cognitive impairment with MMSE \< 20
* Depression with BDI \> 20
* Patients who are unable to give consent to study participation (MMSE \< 20, aphasia)
* Recurrent stroke or myocardial infarction in the period between screening for study participation and start of weight reduction program
* Simultaneous participation in another clinical trial
Minimum Eligible Age

20 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Von Behring-Röntgen Foundation

UNKNOWN

Sponsor Role collaborator

Philipps University Marburg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Yaroslav Winter

Neurologist and Research Fellow

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Neurology, Philipps-University Marburg

Marburg, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yaroslav Winter, MD

Role: CONTACT

Phone: 00496421-5865200

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Winter Yaroslav, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Winter Y, Rohrmann S, Linseisen J, Lanczik O, Ringleb PA, Hebebrand J, Back T. Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks. Stroke. 2008 Dec;39(12):3145-51. doi: 10.1161/STROKEAHA.108.523001. Epub 2008 Aug 14.

Reference Type BACKGROUND
PMID: 18703800 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SCENARIO OP1

Identifier Type: -

Identifier Source: org_study_id